U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07080931) titled 'Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia' on July 15.
Brief Summary: The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.
Study Start Date: Feb. 24
Study Type: INTERVENTIONAL
Condition:
Androgenetic Alopecia
Intervention:
DRUG: 5% minoxidil foam
Participants applied 5% minoxidil foam topically once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.
DRUG: Placebo for 5% Minoxidil F...